Form 4: BioLargo Director Acquires Options as Compensation for Board Service
SEC Form 4 Filing
Director Jack B. Strommen receives options to purchase 65,217 shares of BioLargo stock as compensation for board service.
Summary
- On October 2, 2024, Jack B. Strommen, a director of BioLargo, Inc. (BLGO), reported a transaction involving derivative securities.
- Strommen acquired an option to purchase 65,217 shares of common stock at an exercise price of $0.23.
- The options were granted on September 30, 2024, and are exercisable immediately, expiring on September 30, 2034.
- These options were issued as payment for $15,000 in fees for Strommen's board service during the most recent quarterly period, according to the company's 2024 Equity Incentive Plan.
- Following the transaction, Strommen directly owns 1,982,368 shares of BioLargo common stock.
Sentiment
Score: 6
Explanation: Neutral sentiment as it reflects a routine compensation practice. The option grant is a standard way to compensate directors, aligning their interests with shareholders.
Positives
- The issuance of options aligns the director's interests with those of the shareholders.
- The options serve as compensation for board service, conserving cash for the company.
Industry Context
This type of equity compensation is common for directors of publicly traded companies, particularly smaller firms, to align their interests with shareholders and conserve cash.
Comparison to Industry Standards
- Granting options to directors as compensation is a standard practice, especially in smaller companies like BioLargo.
- The specific amount and terms of the options would need to be compared to similar companies in the environmental technology sector to assess if they are within industry norms.
- Companies like OriginClear or AquaVenture Holdings (prior to acquisition) could be considered for comparison, focusing on their director compensation structures.
Related Party Transactions
- The issuance of options to Jack B. Strommen, a director, is a related party transaction.
Stakeholder Impact
- Shareholders may view the option grant positively as it aligns director interests with company performance.
- The company benefits from conserving cash by using equity for compensation.
Key Dates
| Date | Description |
|---|---|
| July 3, 2017 | Date of Limited Power of Attorney for Section 16 Reporting Obligations. |
| September 30, 2024 | Date options were granted and become exercisable. |
| September 30, 2034 | Expiration date of the options. |
| October 02, 2024 | Date of the transaction and filing of Form 4. |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.